Biomarker Discovery for Suicide Precision Circuit Therapeutics

Starting soon

Conditions studied: Suicidal Thoughts and Behaviors, Major Depressive Episode (MDE)

In brief

This is a prospective observational biomarker study assessing changes in clinical, behavioral, neuroimaging, and neurophysiological measurer following ketamine/esketamine or electroconvulsive therapy (ECT) in adults with suicidal thoughts or behaviors.

Key facts

Study ID

NCT07723066

Run by

Massachusetts General Hospital

People needed

60

Starts

2026-07-01

Expected to finish

2030-08-31

Last updated by the study team

2026-07-23

Who can join

Age: 18 and older, up to 65. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Adults aged 18 to 65 years
• Diagnosis of a major depressive episode associated with Major Depressive Disorder or Bipolar Disorder
• Presence of moderate to severe suicidal thoughts or behaviors, as determined by the Beck Scale for Suicide Ideation (BSSI)
• Scheduled to receive an acute treatment course of electroconvulsive therapy (ECT), intravenous ketamine, or intranasal esketamine as part of routine clinical care
• Ability and willingness to provide informed consent

You may not qualify if…

• Neurological disorders, particularly conditions associated with known structural brain lesions
• Inability to meet MRI safety requirements
• Current alcohol dependence
• Active symptoms of non-alcohol psychoactive substance withdrawal

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.